Is combination treatment with a statin  + a fibrate dangerous? Two case reports

ConclusionsFenofibrate is a safe drug when used as monotherapy. Physicians need to be aware of potentially serious adverse effects such as myopathy and rhabdomyolysis when it is co-administered with statins irrespective of dose. In patients with risk factors for muscle toxicity, such as hepatic impairment, renal insufficiency, diabetes, hypothyroidism and advanced age, CPK levels should be evaluated within 2  weeks and followed more closely. In addition, patients should be instructed to stop statin and fibrate treatment immediately and seek medical advice if significant muscle weakness or pain develops. CPK levels must be monitored and, if tenfold higher than normal, statin treatment should remain disc ontinued.
Source: Drugs and Therapy Perspectives - Category: Drugs & Pharmacology Source Type: research